InMed Pharmaceuticals Inc..
INM.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
InMed Pharmaceuticals Inc. is a biopharmaceutical company specializing in the research, development, and commercialization of novel, cannabinoid-based therapeutics. The company focuses on developing innovative therapies for diseases with high unmet medical needs, particularly in areas such as dermat...Show More
Better Health for All
30
InMed Pharmaceuticals Inc. is entirely focused on developing cannabinoid-based therapeutics for diseases with high unmet medical needs, such as epidermolysis bullosa, Alzheimer's, glaucoma, macular degeneration, autism spectrum disorder, epilepsy, acne, alopecia, inflammatory bowel disease, nausea, and pain.
1
All product candidates, including INM-755, INM-901, INM-088, INM-089, and Cannabidivarin (CBDV), are aimed at providing health benefits, with CBDV specifically noted as non-intoxicating.
2
The company's core business is dedicated to these health-positive pharmaceutical-grade cannabinoids, with no revenue from products with established negative health outcomes.
3
Phase 1 and 2 clinical trials for INM-755 showed a favorable safety profile with no serious drug-related adverse events and very few, transient local adverse events.
4
The company is investing in R&D, including developing a cannabinoid manufacturing system (IntegraSyn™) and conducting molecular analyses for drug candidates like INM-901.
5
Clinical trials are underway for autism, Prader-Willi Syndrome, and ADHD, and a Phase 2 trial for INM-755 was completed, indicating adherence to ethical trial conduct through a double-blind design.
6
Fair Money & Economic Opportunity
0
InMed Pharmaceuticals Inc. is a biopharmaceutical company focused on developing cannabinoid-based therapeutics.
1
The provided articles detail its research, development, clinical trials, and corporate governance. The 'Fair Money & Economic Opportunity' value assesses financial institutions on aspects like lending practices, fee structures, financial inclusion, and wealth-building outcomes for underserved populations. As InMed Pharmaceuticals Inc. does not operate in the financial services sector, the articles contain no relevant data or metrics pertaining to any of the KPIs for this value.
2
Therefore, no KPIs can be scored based on the provided evidence.
Fair Pay & Worker Respect
0
0% of employees are covered by collective bargaining agreements or recognized unions.
1
The company has no public record of labor-law breaches, regulatory actions, or fines.
2
The company offers extended health insurance to all employees.
3
The workforce includes some individuals on interim or consulting agreements, but an overall share of insecure contracts is not provided.
4
Fair Trade & Ethical Sourcing
0
No specific, concrete data points were found in the provided articles to assess InMed Pharmaceuticals Inc. against any of the KPIs for Fair Trade & Ethical Sourcing. The articles explicitly state that no data is available regarding fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clauses in supplier contracts, high-risk materials spend, or supplier diversity spend.
1
Honest & Fair Business
0
No specific, quantitative evidence was found across the provided articles to score any of the KPIs for the 'Honest & Fair Business' value. While articles mention external financial audits by Marcum LLP (2023) and KPMG LLP (2022), and the existence of a Code of Conduct and a formal whistleblower policy, they do not provide the specific percentages, scores, or detailed operational metrics required by the rubric's quantitative thresholds for any KPI.
1
The company received a Nasdaq notice on September 19, 2023, regarding potential delisting due to its average closing bid price falling below $1.00, but this is not an ethics-related regulatory fine.
2
A material weakness related to inadequate resources for financial reporting was noted in the FY2024 audit report, but this does not provide a scorable metric for any KPI.
3
Kind to Animals
0
No evidence available to assess InMed Pharmaceuticals Inc. on Kind to Animals.
No War, No Weapons
0
The company, InMed Pharmaceuticals Inc., is described as a biopharmaceutical company focused on cannabinoid-based therapeutics for medical conditions.
1
The provided articles explicitly state that no data relevant to arms sales, defense industry activities, conflict divestment, or peacebuilding initiatives were found.
2
There is no evidence to suggest the company is involved in any defense-related business, dual-use technologies, sales to embargoed regimes, or any other activities covered by the 'No War, No Weapons' ethical value. Therefore, all KPIs are scored as N/A (0), indicating no applicable defense or arms-related activities in its core business or operations.
Planet-Friendly Business
-20
The company has achieved ISO 14001 Environmental Management Certification.
1
Furthermore, no environmental compliance violations, fines, or compliance issues were reported in the provided articles.
2
Respect for Cultures & Communities
0
No evidence available to assess InMed Pharmaceuticals Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No specific, quantifiable evidence was found in the provided articles to assess the company against any of the 'Safe & Smart Tech' KPIs. Information regarding inadvertent disclosures and a material weakness in internal financial controls does not directly relate to data protection, cybersecurity, or responsible AI practices as defined by the rubric's KPIs.
1
Zero Waste & Sustainable Products
0
No specific, quantifiable data points related to waste management, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, or circular design principles were found in the provided articles.
1
While one article mentions a 'zero-waste protocol'
2
and an investment in 'waste minimization',
3
these do not provide the specific metrics required by the rubric's KPIs, such as waste diversion rates, percentages of recyclable components, or the number and effectiveness of initiatives.